CA2590912A1 — Bicyclic pyrrole derivatives
Assigned to Sumitomo Pharma Co Ltd · Expires 2006-06-29 · 20y expired
What this patent protects
Compounds represented by the general formula (.IOTA.), prodrugs thereof, or pharmaceutically acceptable salts of both are provided as compounds which have high DPP-IV inhibiting activity and are improved in safety, toxicity and so on: (.IOTA.) wherein the solid or broken line bet…
USPTO Abstract
Compounds represented by the general formula (.IOTA.), prodrugs thereof, or pharmaceutically acceptable salts of both are provided as compounds which have high DPP-IV inhibiting activity and are improved in safety, toxicity and so on: (.IOTA.) wherein the solid or broken line between A1 and A2 represents a double bond (A1=A2) or the like; A1 is C(R4) or the like; A2 is nitrogen or the like; R1 is hydrogen, optionally substituted alkyl, or the like; R2 is hydrogen, optionally substituted alkyl, or the like; R3 is hydrogen, halogeno, or the like; R4 is hydrogen, hydroxyl, halogeno, or the like; and Y is a group represented by the general formula (A) or the like: (A) [wherein m1 is 0, 1, 2 or 3; and the group (A) may be freed from R6 or substituted with one or two R6's which are each independently halogeno or the like].
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.